Despite an earlier downgrade to Market Perform by RBC this morning, Wells Fargo says Celgene (CELG -0.6%) looks attractive at current levels. After meeting with management, Wells says it's pleased with the way Q2 is going and thinks the stock could rally on the back of the E.U.'s label decision on Revlimid, and that the drug is positioned for solid growth.